Brokers Issue Forecasts for Cerus FY2026 Earnings

Cerus Co. (NASDAQ:CERS - Free Report) - Research analysts at Cantor Fitzgerald issued their FY2026 EPS estimates for Cerus in a note issued to investors on Monday, June 9th. Cantor Fitzgerald analyst R. Osborn forecasts that the biotechnology company will post earnings per share of $0.00 for the year. Cantor Fitzgerald currently has a "Overweight" rating and a $4.00 price target on the stock. The consensus estimate for Cerus' current full-year earnings is ($0.08) per share.

Cerus (NASDAQ:CERS - Get Free Report) last released its quarterly earnings data on Thursday, May 1st. The biotechnology company reported ($0.04) earnings per share for the quarter, beating analysts' consensus estimates of ($0.05) by $0.01. Cerus had a negative return on equity of 40.55% and a negative net margin of 11.60%. The business had revenue of $43.24 million during the quarter, compared to analyst estimates of $47.44 million.

Cerus Stock Performance

CERS stock traded down $0.05 during trading on Tuesday, hitting $1.32. 1,010,583 shares of the company traded hands, compared to its average volume of 1,307,816. The stock's 50-day simple moving average is $1.33 and its 200 day simple moving average is $1.55. Cerus has a 1 year low of $1.12 and a 1 year high of $2.54. The company has a market cap of $252.33 million, a PE ratio of -12.00 and a beta of 1.55. The company has a debt-to-equity ratio of 1.19, a current ratio of 2.59 and a quick ratio of 1.92.

Institutional Investors Weigh In On Cerus

A number of institutional investors have recently modified their holdings of the business. Rockport Wealth LLC purchased a new position in Cerus during the fourth quarter worth approximately $25,000. Merit Financial Group LLC acquired a new stake in Cerus in the 1st quarter valued at $25,000. Wealth Enhancement Advisory Services LLC purchased a new stake in Cerus in the 4th quarter worth $25,000. Cibc World Markets Corp acquired a new position in Cerus during the fourth quarter worth $26,000. Finally, Dynamic Technology Lab Private Ltd acquired a new position in Cerus during the first quarter worth $32,000. 78.37% of the stock is currently owned by institutional investors and hedge funds.

Cerus Company Profile

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.